Sigyn Therapeutics has announced the launch of an initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy. This initiative is significant as it addresses a critical health issue affecting former professional athletes who experience significantly higher rates of neurodegenerative diseases compared to the general population, including amyotrophic lateral sclerosis, Parkinson's disease, and CTE.
The importance of this initiative stems from recent research findings that reveal chronic inflammation as the principal driver of CTE progression. Last month, researchers at Trinity College Dublin reported that the protective blood-brain barrier can be compromised by chronic inflammation and remain leaky for decades after an athlete retires from sports involving repetitive head trauma. This allows inflammatory and pathogenic molecules to leak into the brain, triggering neuroinflammation that can accelerate abnormal accumulation of tau-protein, the hallmark indicator of CTE.
Based on this discovery, many former NFL players could be living in a persistent state of hyper-inflammation that increases their risk for CTE. In response, Sigyn Therapeutics is establishing a collaborative initiative with three primary objectives: evaluate the feasibility of CardioDialysis to reduce circulating inflammatory molecules that fuel CTE progression; complete an evaluation of blood-based neuron-derived exosome assays to monitor CTE progression and response to therapies; and complete the evaluation of other candidate therapies including a tau vaccine and brain-delivered anti-inflammatory drug agent.
Jim Joyce, CEO of Sigyn Therapeutics, stated that based on his previous participation in two landmark studies of CTE in former NFL players, the knowledge that the brains of collision sport athletes can remain permeable for decades opens the door to new strategies to diagnose CTE in the living and for treating the disease through targeted control of inflammation. The initiative represents a potential shift in how CTE might be addressed in living patients rather than only being diagnosed post-mortem.
CardioDialysis represents a novel approach in the emerging field of subtractive medicine. It is the first technology to integrate plasma separation and therapeutic adsorption into a single device that enables continuous broad-spectrum clearance of both inflammatory and pathogenic molecules from the bloodstream. This includes clearance of inflammatory cytokines TNF-alpha, IL-1 beta, IL-6, as well as bacterial endotoxin, which are among the most relevant blood-brain barrier-crossing contributors to CTE progression.
Related to CTE, excessive inflammatory cytokine production also increases gut permeability, allowing bacterial endotoxin to leak into the bloodstream, which further amplifies inflammation into the chronic self-perpetuating loop of neuroinflammation observed by Trinity College researchers. The potential application of CardioDialysis in this context could address multiple pathways contributing to CTE progression simultaneously. More information about Sigyn Therapeutics can be found at https://www.SigynTherapeutics.com.
The initiative's broader implications extend beyond former NFL players to potentially benefit other populations affected by neuroinflammatory disorders. If successful, the technologies being evaluated could provide new approaches to managing CTE and related conditions where inflammation plays a key role in disease progression. The original release can be viewed on https://www.newmediawire.com.
